Capsules: 'National Dialogue' Urged On Cost Of New Hepatitis C Drug

Now on Kaiser Health News’ blog, Julie Appleby reports on the latest regarding Sovaldi, a $1,000-a-pill treatment for Hepatitis C: “While the drug is a significant advance over older treatments for the viral liver disease, the price set by the company 'represents an abuse of market power, said John Rother, president and CEO of the National Coalition on Health Care, which includes businesses, unions, insurers, consumers and some drugmakers, including the Generic Pharmaceutical Association. On Wednesday, the group urged a 'national dialogue' on the cost, saying Sovaldi’s price tag threatens the budgets of government run-health programs as well as the premiums for everyone who has private insurance” (Appleby, 5/28). Check out what else is on the blog.

This is part of Kaiser Health News' Daily Report - a summary of health policy coverage from major news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Report here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.